Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy

Journal of Psychiatric Research

Volumn 41, Issue 3-4, 2007, Pages 305-310

  Lipkovich, I ^a   Deberdt, W ^a   Csernansky, J G ^b   Buckley, P ^c   Peuskens, J ^d   Kollack Walker, S ^a   Zhang, Y ^e   Liu Seifert, H ^a   Houston, J P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Dose; Olanzapine; Predictors; Relapse; Schizophrenia

Indexed keywords

OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGGRESSION; AGITATION; ANXIETY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HOSTILITY; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PATIENT COMPLIANCE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PSYCHOSIS; RATING SCALE; RELAPSE; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENTIATION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA;

EID: 33845215824     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2006.07.016     Document Type: Article

References (17)

1. Ayuso-Gutierrez J.L., and Rio Vega J.M. Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research 28 (1997) 199-206
2. Barnes T.R. A rating scale for drug-induced akathisia. British Journal of Psychiatry 154 (1989) 672-676
3. Breier A., Berg P.H., Thakore J.H., Naber D., Gattaz W.F., Cavazzoni P., et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. American Journal of Psychiatry 162 (2005) 1879-1887
4. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 37 (1999) 177-193
5. Csernansky J.G., and Schuchart E.K. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16 (2002) 473-484
6. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (Publication ADM 76-338). In: Rockville, MD, US Dept of Health, Education, and Welfare: 1976. p. 218-22.
7. Heinrichs D.W., Hanlon T.E., and Carpenter Jr. W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10 (1984) 388-398
8. Kay S.R., Opler L.A., and Fjalland B. Positive and negative syndrome scale (PANSS) manual (1986), Multi-Health Systems, North Tonawanda, New York
9. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal Psychiatry 160 (2003) 1209-1222
10. Lieberman J.A. Prediction of outcome in first-episode schizophrenia. Journal of Clinical Psychiatry 54 Suppl (1993) 13-17
11. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., and Perkins D.O. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
12. Liu-Seifert H., and Kinon B. Predominance of psychiatric-based reasons for antipsychotic treatment discontinuation. Neuropsychopharmacology 29 (2004) S127-S128
13. Marder S.R., Davis J.M., and Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychiatry 58 (1997) 538-546
14. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Archives of General Psychiatry 54 (1997) 453-463
15. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementary 212 (1970) 11-19
16. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 17 (1997) 407-418
17. Weiss U., Marksteiner J., Kemmmler G., Saria A., and Aichhorn W. Effects of age and sex on olanzapine plasma concentrations. Journal of Clinical Psychopharmacology 25 (2005) 570-574